Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer
Pancreatic cancer (PC) is one of the most lethal tumor malignancies, which has a poor prognosis and can be the cause of death despite tumor removal. New molecular investigations for therapeutic purposes have shown the expression of HER3 in pancreatic adenocarcinoma. Family receptors HER3 pl...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krupanidhi College of Pharmacy
2024-06-01
|
| Series: | Journal of Pharmaceutical Research |
| Online Access: | https://jopcr.com/articles/immunohistochemical-assessment-of-her3-expression-in-pancreatic-cancer |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849230197683912704 |
|---|---|
| author | Hosnie Hoseini Azade Sarani |
| author_facet | Hosnie Hoseini Azade Sarani |
| author_sort | Hosnie Hoseini |
| collection | DOAJ |
| description | Pancreatic cancer (PC) is one of the most lethal tumor malignancies, which has a poor prognosis and can be the cause of death despite tumor removal. New molecular investigations for therapeutic purposes have shown the expression of HER3 in pancreatic adenocarcinoma. Family receptors HER3 play an effective role in malignancies such as lung and colon cancer. The aim of this study is to investigate the expression of HER3 in pancreatic cancer samples and the relationship between the expression of the receptor HER3 and the clinical complications of patients. Samples were taken from 75 patients with pancreatic cancer and subjected to immunohistochemical staining to evaluate the expression. Based on the intensity of staining, scores were assigned to each sample for HER3 receptor. Scores of +2 or +3 were defined as positive staining. The obtained data were analyzed using SPSS 16 software and Chi-square tests. P<0.05 was considered statistically significant. The results showed the expression of HER3 in normal pancreatic tissue. The expression decreased from the early to late stage (p=0.05). Multivariate survival analysis showed that only stage had independent prognostic value (p=0.015). HER3 expressed in normal pancreatic tissue, but the expression is lost in pancreatic cancer. According to the study, it seems that targeted treatment in pancreatic cancer has no relationship with expression. Keywords EGFR, HER3, Pancreatic adenocarcinoma, Prognosis |
| format | Article |
| id | doaj-art-eb1c9da00c2a4ebf9cdc05c76c5b130c |
| institution | Kabale University |
| issn | 0973-7200 2454-8405 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Krupanidhi College of Pharmacy |
| record_format | Article |
| series | Journal of Pharmaceutical Research |
| spelling | doaj-art-eb1c9da00c2a4ebf9cdc05c76c5b130c2025-08-21T09:34:09ZengKrupanidhi College of PharmacyJournal of Pharmaceutical Research0973-72002454-84052024-06-0123212412810.18579/jopcr/v23.2.1Immunohistochemical Assessment of HER3 Expression in Pancreatic CancerHosnie Hoseini Azade Sarani Pancreatic cancer (PC) is one of the most lethal tumor malignancies, which has a poor prognosis and can be the cause of death despite tumor removal. New molecular investigations for therapeutic purposes have shown the expression of HER3 in pancreatic adenocarcinoma. Family receptors HER3 play an effective role in malignancies such as lung and colon cancer. The aim of this study is to investigate the expression of HER3 in pancreatic cancer samples and the relationship between the expression of the receptor HER3 and the clinical complications of patients. Samples were taken from 75 patients with pancreatic cancer and subjected to immunohistochemical staining to evaluate the expression. Based on the intensity of staining, scores were assigned to each sample for HER3 receptor. Scores of +2 or +3 were defined as positive staining. The obtained data were analyzed using SPSS 16 software and Chi-square tests. P<0.05 was considered statistically significant. The results showed the expression of HER3 in normal pancreatic tissue. The expression decreased from the early to late stage (p=0.05). Multivariate survival analysis showed that only stage had independent prognostic value (p=0.015). HER3 expressed in normal pancreatic tissue, but the expression is lost in pancreatic cancer. According to the study, it seems that targeted treatment in pancreatic cancer has no relationship with expression. Keywords EGFR, HER3, Pancreatic adenocarcinoma, Prognosishttps://jopcr.com/articles/immunohistochemical-assessment-of-her3-expression-in-pancreatic-cancer |
| spellingShingle | Hosnie Hoseini Azade Sarani Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer Journal of Pharmaceutical Research |
| title | Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer |
| title_full | Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer |
| title_fullStr | Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer |
| title_full_unstemmed | Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer |
| title_short | Immunohistochemical Assessment of HER3 Expression in Pancreatic Cancer |
| title_sort | immunohistochemical assessment of her3 expression in pancreatic cancer |
| url | https://jopcr.com/articles/immunohistochemical-assessment-of-her3-expression-in-pancreatic-cancer |
| work_keys_str_mv | AT hosniehoseini immunohistochemicalassessmentofher3expressioninpancreaticcancer AT azadesarani immunohistochemicalassessmentofher3expressioninpancreaticcancer |